| Assessment Status | NCPE Assessment Process complete |
| HTA ID | 23045 |
| Drug | Brexucabtagene Autoleucel |
| Brand | Tecartus® |
| Indication | Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
| Assessment Process | |
| Rapid review commissioned | 24/07/2023 |
| Rapid review completed | 10/08/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brexucabtagene autoleucel compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/08/2023 |
| Pre-submission consultation with Applicant | 09/10/2023 |
| Full submission received from Applicant | 18/01/2024 |
| Preliminary review sent to Applicant | 18/09/2024 |
| NCPE assessment re-commenced | 17/10/2024 |
| Factual accuracy sent to Applicant | 20/12/2024 |
| NCPE assessment re-commenced | 10/01/2025 |
| NCPE assessment completed | 23/01/2025 |
| NCPE assessment outcome | The NCPE recommends that brexu-cel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
